Cancer treatment: A researcher makes breakthrough immunotherapy discovery

October 24, 2019

Dr Christopher E. Rudd, a researcher at the Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) and Université de Montréal, has discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours. The results of the study have just been published in the respected journal Nature.

"Our work has identified a new T-cell protein that interacts with the key receptor that detects and responds to cancer antigens," says Prof. Rudd. "We have used those findings to develop a new form of immunotherapy in which hyperactivation of T cells enables them to penetrate and attack tumours. This discovery demonstrates that modulation of the identified protein can activate the immune system and lead to destruction of the cancer cells."

To date, the effectiveness of the new form of immunotherapy against leukemia and some skin cancers has been demonstrated in animals. The next stage will be clinical trials with human subjects.

"This discovery is a scientific breakthrough that will have significantly enhance the immune system's effectiveness in eliminating cancer cells," says Dr. Denis-Claude Roy, scientific and medical director of the Center of Excellence in Cellular Therapy and CR-HMR.

Eventually, this approach could also improve the effectiveness of the new CAR?T cell therapy currently being used at Hôpital Maisonneuve-Rosemont.

Dr Christopher E. Rudd is a professor in the Department of Microbiology, Infection and Immunology, Université de Montréal, and Director of the Cell Signalling in Immunotherapy Unit at CR-HMR. The research was conducted in part while he was a professor at Cambridge University in England and then in his lab at CR-HMR and at Université de Montréal. Dr. Youg Raj Thaker of Cambridge University and Essex University in England, and Dr. Monika Raab and Dr. Klaus Strebhardt of the J.W. Goethe University Medical School in Frankfurt, Germany, were also involved in the research.
-end-


University of Montreal

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.